Vericel to Present at the Ladenburg Thalmann Healthcare Conference

Vericel Corporation (NASDAQ:VCEL) announced that Chief Financial Officer Joe Mara will present at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:30 p.m. ET.

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that Chief Financial Officer Joe Mara will present at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:30 p.m. ET. This event highlights the company’s commitment to sharing insights about its advanced therapies in sports medicine and burn care. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website, ensuring that stakeholders can stay informed about the company’s developments.

Argus Session date unavailable

-3.89% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was -3.89%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The presentation is scheduled to begin at 2:30 p.m. ET on Thursday, September 29, 2022.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contacts: 
Eric Burns
ir@vcel.com 
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Joe Mara present at the Ladenburg Thalmann Healthcare Conference for VCEL?

Joe Mara will present on September 29, 2022, at 2:30 p.m. ET.

How can I watch the Vericel Corporation presentation at the healthcare conference?

The presentation will be available through a webcast on the Investor Relations section of the Vericel Corporation website.

What products does Vericel Corporation focus on?

Vericel focuses on advanced therapies for sports medicine and severe burn care, including MACI® and Epicel®.

What is MACI® used for by Vericel?

MACI® is used for the repair of symptomatic, full-thickness cartilage defects in the knee.

What is Epicel® and its use in burn care?

Epicel® is a permanent skin replacement for patients with deep dermal or full thickness burns covering 30% or more of total body surface area.